The assistant professor of clinical pediatrics at Indiana University School of Medicine, and the chair of the AASM’s Artificial Intelligence in Sleep Medicine Committee, spoke about the ability of AI algorithms as tools in clinical care. [WATCH TIME: 3 minutes]
The radiation oncologist at Cooperman Barnabas Medical Center talked about how trigeminal neuralgia can be effectively treated with stereotactic radiosurgery using the CyberKnife offering pain relief without the need for invasive surgery. [WATCH TIME: 6 minutes]
In a time when complex medical communication to the public is on display, the need to ensure patient comprehension is of utmost importance for vascular neurologists.
The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 3 minutes]
Episode 37 of the AUPN Leadership Minute features David G. Standaert, MD, PhD, of the University of Alabama at Birmingham; and Erica A. Schuyler, MD, of the University of Connecticut. [WATCH TIME: 5 minutes]
Fatigue, although not immediately visible, is among the most debilitating symptoms of multiple sclerosis, affecting not only patients' day-to-day functioning but their quality of life.
At the 2023 MDA conference, the professor for human genetics and neurology at the University of Miami Miller School of Medicine talked about the role of genetics in neuromuscular diseases and potential therapies. [WATCH TIME: 5 minutes]
Advocacy organization Cure SMA provides insight on the importance of continuing to push for standardized newborn screening and how it can positively impact outcomes in SMA.
In honor of Rare Disease Day, the vice president of public policy and advocacy at the Muscular Dystrophy Association shared his perspective of advocacy and policy progress in the realm of rare neuromuscular diseases. [WATCH TIME: 6 minutes]
The division director of pediatric neurology, and director of the pediatric sleep program at Cohen, Children's Medical Center, Northwell Health, spoke about sudden unexpected death in epilepsy and sleep at the 2022 AES Conference. [WATCH TIME: 3 minutes]
The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
The course directors of the 2023 ATRMD Congress provided an overview of the upcoming meeting, and the educational benefits clinicians can gain from attending. [WATCH TIME: 6 minutes]
The assistant professor at Cleveland Clinic discussed findings from a recently published study that provided insights on the understanding of the molecular basis for female predominance in Alzheimer disease. [WATCH TIME: 3 minutes]
AUPN Leading Edge Episode 4 features Rohit Das, MD, and Joseph R. Berger, MD, who discuss how neurologists are undervalued in academic and non-academic settings when their compensation is predicated on RVUs alone. [LISTEN TIME: 26 minutes]
The Cleveland Clinic researcher discussed the unknowns about Parkinson disease dementia and what has been previously observed in clinical studies.
The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals discussed how sodium oxybate has evolved over the years and the educational aspects of cardiovascular implications patients and clinicians should be aware of. [WATCH TIME: 3 minutes]
The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
The nurse practitioner in the movement disorder division at Georgetown University Hospital discussed differences in available therapies for movement disorders versus multiple sclerosis and using a chronic care management model in Parkinson disease. [WATCH TIME: 5 minutes]
The associate professor of neurosurgery at Robert Wood Johnson Medical School talked about minimally invasive techniques and neurostimulation strategies to make epilepsy surgery safer and more effective. [WATCH TIME: 7 minutes]
Expert neurologists share thoughts on how to improve patient/physician communication and how listening to the patient needs will aid in managing MG.
The associate professor at Yeshiva University and Albert Einstein College of Medicine explored the challenge of discussing lifestyle changes for patients with migraine, noting that lifestyle modifications can be a valuable addition to migraine treatment. [WATCH TIME: 3 minutes]
The graduate student at the University of Michigan provided insight on her study examining longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders. [WATCH TIME: 3 minutes]
Many programs and activities at the 2023 CMSC Annual Meeting focused on burnout prevention and supporting the current and future MS care workforce.
Expert neurologists provide insight on unmet needs, challenges to improve access to care, and highlight clinical pearls for the management of OFF episodes in Parkinson disease.
The professor of neurology, psychiatry, and pharmacology at the NYU Grossman School of Medicine commented on the differences in mechanisms and clinical trial data between lecanemab and donanemab. [WATCH TIME: 5 minutes]
At the 2023 MDA Conference, a neurology nurse practitioner in the Neuromuscular Division at Washington University in St. Louis talked about adverse event management of gene therapies in Duchenne muscular dystrophy. [WATCH TIME: 2 minutes]
The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.
The associate professor of neurology at Albert Einstein College of Medicine talked about a review on neonatal seizures recently published in the New England Journal of Medicine. [WATCH TIME: 5 minutes]
Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population: Alzheimer disease and AD-related dementias.